University Medical Center Groningen
Groningen, 9700 RB, Netherlands
NCT Number: NCT02912624
Circulatory shock is a condition of generalized inadequate blood flow through the body, leading to insufficient tissue perfusion and inadequate delivery of oxygen and other nutrients, to the extent that tissues are damaged. Four basic mechanisms of circulatory failure are distinguished, caused by a scale of underlying illnesses: distributive, hypovolemic, obstructive and cardiogenic shock. The last three types are characterized by a low cardiac output and hypovolemia. Distributive shock is characterized by peripheral circulation failure, with a low systemic vascular resistance, a disturbed microcirculation and a high cardiac output. Frequently, these forms overlap.
Shock is a common problem in the intensive care unit (ICU) as it affects about one third of the patients. Septic shock appears to be the most common type, followed by cardiogenic and hypovolemic shock. The diagnosis of shock is based on clinical examination with use of well-known circulatory parameters such as blood pressure and heart rate; biochemical parameters such as lactate and direct (semi-)invasive measurement of cardiac output and other variables.
Since cardiac output is an important determinant of oxygen delivery, many different methods of measuring cardiac output have been suggested. These methods range from non-invasive to invasive measurements with central lining. The most invasive method, the pulmonary artery catheter (PAC) has long been considered the optimal form of monitoring cardiac output by using thermodilution. However, this technique is associated with adverse events, such as bleeding, and there is no clear evidence of improved outcome. Therefore, numerous other techniques have been proposed, ranging from systems that use the dilution technique but only require central venous and peripheral artery lines; to less invasive tools that estimate cardiac output based on the arterial pressure waveform; and to non-invasive echocardiography.
Despite technical advances, much remains unknown about the value of conventionally used hemodynamic parameters for estimating cardiac output. A distinction between macro- and microcirculatory parameters can be made. Commonly used macro-circulatory parameters are heart rate, systolic and diastolic blood pressure, mean arterial pressure and central venous pressure. Lactate is used as a proxy for microcirculatory status. Over the years several other measurements have been suggested to improve insight in the hemodynamics of a certain patient or a group of patients. Skin temperature, capillary refill, mottling score and urinary output are used for hemodynamic assessment of the peripheral circulation and tissue perfusion. Most of these parameters have not been evaluated in a large prospective study and especially a combination of all these parameters has not directly been correlated to cardiac output.
More knowledge on the predictive value of all hemodynamic parameters in estimating cardiac output could assist physicians in earlier detection of impaired hemodynamics without the need for invasive or advanced methods. In this study the investigators aim to evaluate all hemodynamic parameters in a large unselected population of critically ill patients and to correlate them to cardiac output.
Purpose:
The purpose of this study is to create an infrastructure for a registry flexible to incorporate temporarily added specific research questions on the outcome of critically ill patients.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Groningen, 9700 RB, Netherlands
Registry procedures:
Eligible patients will be included within 24 hours after their arrival on the Intensive Care Unit. After inclusion all study parameters will be obtained once through physical examination combined with transthoracic echocardiography. Mortality will be assessed at 90 days after admission. In addition, mortality follow-up will be cut-off at 7 and 30 days after admission.
Monitoring:
Monitoring will be performed by independent researchers of the department of anaesthesiology of the UMCG. Audits are planned to take place once a year.
Quality assurance plan:
Recruitment:
Inclusion of patients and measurements of variables (both conventional hemodynamic variables and cardiac output) will be performed by the study coordinator or a co-researcher under supervision and responsibility of the principle investigator. Informed consent will be obtained.
Source data verification:
At inclusion all conventional hemodynamic variables are derived by physical examination and recording data from the basic hemodynamic monitoring (Philips ImageVue monitor with tracing of heart rate, electrocardiogram (ECG), SpO2, arterial pressure from arterial line pressure measurement and/or from non-invasively blood pressure monitoring). In addition, a transthoracic echocardiography (TTE) will be performed to non-invasively determine the cardiac output by using the diameter of the aortic annulus, the velocity time integral (VTI) of the Doppler flow and the heart rate. All variables are predefined (see data dictionary) to standardize all measurements by student researchers.
For the performance of the TTE the student researchers will be trained to visualize the parasternal 2 chamber view, apical 4 and 5 chamber view according to the international standards (ACC/ESC) and to measure the left ventricular outflow tract VTI and the diameter of the aortic annulus. The training was given by an experienced cardiologist-intensivist. All measurements were validated by an echocardiography technician (core laboratory) who was blinded for all other measurement outcomes. General patient characteristics and laboratory measurements were recorded from electronic patient charts and the APACHE II and IV, Simplified Acute Physiology Score II (SAPS) scores are extracted from our local National Intensive Care Evaluation database. Follow-up of all-cause mortality is acquired using the municipal personal records database.
Standard Operation Procedures
Data collection:
Within 24 hours of ICU admission, all hemodynamic variables will be obtained through a onetime physical examination combined with transthoracic echocardiography. Other variables (i.e. lab values) will be obtained from the electronic patient charts at a later moment. The rationale and specific details of measuring each variable are described extensively below.
Systemic circulatory variables:
Micro- and peripheral circulatory variables:
To objectify the skin temperature, the use of a central-to-peripheral and peripheral-to-ambient temperature difference (respectively dTc-p and dTp-a) or the forearm-to-finger skin-temperature gradient (Tskin-diff) have been proposed in literature. The investigators will make use of the central-to-peripheral measurements:
Other variables:
After the physical examination has been performed, information on the following general characteristics will be extracted from patient files: demographic data, diagnoses and severity of illness as evaluated by the APACHE II and IV scores, Simplified Acute Physiology Score II (SAPS) and the Sequential Organ Failure Assessment (SOFA). Furthermore the investigators will collect EMV scores, lab values (details are described above), urine output (details are described above), routine admission ECG's and routine admission thorax photo's. After 90 days the investigators will assess the patient files again to gather information on total ICU stay in days and 7-, 28- and 90-day mortality.
Data management:
Data will be recorded using OpenClinica and transferred for analysis. After transfer from OpenClinica, all data will be managed in a database created using Stata version 14.1 (StataCorp, College Station, TX) All study subjects will receive a study subject ID, compiled of the study name and their inclusion number. This study subject ID will be used in both OpenClinica and Stata. Only a researcher with 'study director' account properties in OpenClinica will be able to link study subject ID to patient number. Images will be saved anonymously and will be coded in a systematic fashion, using the study subject ID, session number, and image contents.
Sample size assessment:
There are no previous studies with data on including a combination of all available hemodynamic variables into one model estimating cardiac output and mortality. This makes it difficult to calculate sample size. The investigators will therefore make an estimation based on the number of ICU admissions per year. Each year 3000 patients are admitted to one of four ICU units. Approximately 1500 of these admissions are unplanned emergency admissions. The investigators estimate that half of these unplanned admissions fulfill the inclusion criteria. This leaves 750 patients eligible for inclusion. However, the investigators assume that they will not be able to include all eligible patients for logistic and practical reasons. Therefore the investigators aim to include 400 patients per year. With emergency admission critical care mortality approaching 25% this will enable us to include at least ten variables in the final model for predicting mortality (acknowledging that at least 10 events are necessary for each variable included in the final model). We will describe the power and detectable difference in a detailed statistical analysis plan (SAP).
Plan for missing data:
Primary analyses will be performed with imputation for missing data using multiple imputations. Robustness of conclusions will be checked by secondary sensitivity analyses only including available data. We will describe additional information in a detailed statistical analysis plan.
Statistical analysis plan:
The investigators will use the general characteristics to create a baseline table. Statistical analyses will be performed using the Stata (StataCorp, College Station, TX). Data will be presented as means with standard deviation if normally distributed or as medians with ranges in case of skewed data.
Univariate analyses will be conducted and all variables with p<0.1 will be included in the multivariate models. Multivariate analyses will be conducted using a stepwise model. Cardiac output will be modeled using linear regression and mortality will be modeled using logistic regression. All analyses will be adjusted for age and gender; other general characteristics will not be added to the model standardly. All analyses will be tested two-sided and p-values of less than 0.015 will be considered statistical significant. Multiplicity issues are described in our detailed SAP.
If sample size permits, the investigators will conduct an analysis in different subpopulations. Examples of subpopulations that may be eligible for further analysis are those with different types of shock (distributive, obstructive, hypovolemic, cardiogenic), CVVH, heart failure by any cause, myocardial infarction, atrial fibrillation or surgery versus no-surgery patient groups.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Immediately
Primary outcome of the basic study, answering our diagnostic research question
We calculated cardiac index, which was derived from cardiac output. Cardiac output has been measured with the cardiac probe M3S of M4S with default cardiac imaging setting of the General Electric Vivid-S6 mobile ultrasound machine. Two views were obtained: the parasternal long axis (PLAX) and the apical five chamber view (AP5CH). The PLAX was used as the primary view to measure the left ventricular outflow tract (LVOT) diameter. The AP5CH view was used to measure the velocity time integral (VTI) using the pulse wave Doppler signal in the LVOT. Cardiac output was calculated on the ultrasound machine according to the formula: Cardiac output (L/min)=heart rate ∙VTI∙π∙(1/2∙LVOT)^2
Clinical examination findings have been collected during a one-time physical examination, which is further specified at the study description section.
Time frame: 90 days
Primary outcome of the basic study, answering our prognostic research question.
Clinical examination findings, as well are specified at the study description section.
Biochemical values are serum lactate, creatinine and hemoglobine (see study description).
Hemodynamic variables are obtained from advanced patient monitoring devices, such as invasive central venous or arterial blood pressures, echocardiographic measurements, etc.
Follow-up on all-cause mortality will be obtained from the municipal personal records database. Analysis of mortality will be performed using time-to-event data (patients were censored at 90-days of follow-up).
Time frame: Immediately
Secondary outcome of the basic study, answering our diagnostic research question.
For this outcome, we will determine the cut-offs as follows:
Time frame: Immediately
Secondary outcome of the basic study, answering our diagnostic research question.
If the sample size permits, we will conduct subgroup analysis in different subpopulations. We will create the following subgroups in the basic study and test both our prognostic and diagnostic hypotheses on:
Time frame: 30 days
Secondary outcome of the basic study, answering our prognostic research question.
This will be a sensitivity analyses on different follow-up times of mortality.
Time frame: 90 days
Secondary outcome of the basic study, answering our prognostic research question.
Variables not visible to caregivers are some of our clinical examination findings and cardiac index measurements. Clinical examination findings that were not shared with caregivers, were: capillary refill times, mottling scores and peripheral temperature measurements.
Time frame: 90 days
Secondary outcome of the basic study, answering our prognostic research question.
If the sample size permits, we will conduct subgroup analysis in different subpopulations. We will create the following subgroups in the basic study and test both our prognostic and diagnostic hypotheses on:
Time frame: Immediately
Substudy 1 - primary outcome
StO2 was measured by NIRS with the Inspectra StO2 tissue oxygenation monitor, model 650 (Hutchinson Technology, Inc., Hutchinson, Minnesota, USA). We used a 15-mm probe to measure the StO2 at a depth of 14mm at two sites: the thenar eminence and the distal end of the vastus medialis muscle. The average StO2 value was calculated over 30 seconds after one minute of signal stabilisation.
Time frame: Immediately
Substudy 1 - secondary outcome
Time frame: Immediately
Substudy 1 - secondary outcome
Time frame: Immediately
Substudy 2 - primary outcome
Pulmonary ultrasound was conducted with the cardiac probe M3S of M4S with default cardiac imaging and maximal frequency (3.6 MHz) setting of the General Electric Vivid-S6 mobile ultrasound machine. We measured the presence or absence of B-lines at the six locations specified in the BLUE-protocol. The presence of a B-profile was defined by three or more B lines observed in at least three of the six BLUE points, or in two of the four lower BLUE points.
Pulmonary oedema was diagnosed by the radiologist who reviewed chest radiographs as part of daily care. The radiologist was blinded for the variables collected in our study.
Time frame: Immediately
Substudy 2 - primary outcome
Time frame: Immediately
Substudy 2 - secondary outcome
The presence of a B-profile was defined by three or more B lines observed in at least three of the six BLUE points, or in two of the four lower BLUE points.
Time frame: Immediately
Substudy 3 - primary outcome
Cardiac output was measured using the same ultrasound machine, probes, views and formulas as described in the primary outcome of the basic study.
During the PEEP-challenge, an additional 10 cm H2O of PEEP was temporarily applied when supervised by the treating ICU physician. The PEEP was elevated for a maximum duration of 5 minutes during which the changes in cardiac output, heart rate, blood pressures and central venous pressure were recorded.
Time frame: 90 days
Substudy 4 - primary outcome
TAPSE and RV s' have been measured with the cardiac probe M3S of M4S with default cardiac imaging setting of the General Electric Vivid-S6 mobile ultrasound machine. Both measurements were obtained in the AP4CH view. TAPSE was assessed in M-mode, after placing the cursor on the junction of the tricuspid valve and the RV free wall. RV s' was assessed in the tissue velocity imaging mode highlighting the area of interest. The pulsed Doppler sample volume was placed at the tricuspid level of the RV free (i.e. lateral) wall and the longitudinal velocity of excursion was measured.
Time frame: Immediately
Substudy 4 - secondary outcome
Time frame: Immediately
Substudy 5 - primary outcome
Common carotid artery, subclavian artery, and common femoral artery flows have been measured with the linear probe 8L or 9L and default carotid setting of the General Electric Vivid-S6 mobile ultrasound machine.
Time frame: 90 days
Substudy 5 - secondary outcome
A proxy for abdominal flow was calculated by subtracting flow over both left and right carotid, subclavian and femoral arteries from the cardiac output.
AKI was established and classified following the kidney disease: improving global outcomes (KDIGO) criteria. Urine output and serum creatinine measurements from the first 72 hours of inclusion were analysed to establish and classify AKI for each patient.
Time frame: 24 hours
Substudy 6 - primary outcome
Cardiac output has been estimated with the FloTrac (Edwards Lifesciences, Irvine, California, USA) and a monitor to compute stroke volume and cardiac output (Vigileo, Edwards Lifesciences, Irvine, California, USA). The FloTrac analyses the arterial pressure waveform to compute stroke volume and cardiac output. The estimated cardiac output was compared to the cardiac output measured with the General Electric Vivid-S6 mobile ultrasound machine.
Time frame: 24 hours
Substudy 6 - secondary outcome
Time frame: 24 hours
Substudy 7 - primary outcome
We repeated the measurements of the variables collected in the basic study, sub-study 2, and sub-study 4. We performed these measurements 24 hours (minimum 22 to maximum 26 hours) after the first measurement and calculated differences. The sign of the variable indicates whether a variable has either increased (positive number) or decreased (negative number).
Time frame: 90 days
Substudy 7 - secondary outcome
Time frame: Immediately
Substudy 8 - primary outcome
Right ventricle diameters and tricuspid regurgitation velocity have been measured with the cardiac probe M3S of M4S with default cardiac imaging setting of the General Electric Vivid-S6 mobile ultrasound machine. The measurements were obtained in the AP4CH view with a right ventricle centred view.
AKI was established and classified following the kidney disease: improving global outcomes (KDIGO) criteria. Urine output and serum creatinine measurements from the first 72 hours of inclusion were analysed to establish and classify AKI for each patient.
Time frame: Immediately
Substudy 8 - primary outcome
Time frame: 90 days
Substudy 8 - secondary outcome
Time frame: Immediately
Substudy 8 - secondary outcome
Time frame: Immediately
Substudy 9 - primary outcome
Every passive leg raising manoeuvre was conducted for a maximum duration of 60 seconds during which the changes in cardiac output, heart rate, blood pressures, central venous pressure, and EtCO2 were recorded. Fluid responsiveness was diagnosed when cardiac output increased with 15% after the PLR-test.
Time frame: Immediately
Substudy 9 - primary outcome
During the fluid responsiveness study, two different PLR tests were applied when supervised by the treating ICU physician.
Time frame: Immediately
Substudy 9 - secondary outcome
Fluid responsiveness was diagnosed when cardiac output increased with 15% after the PLR-test. The PEEP-challenge was conducted in a similar manner as described in sub-study 3.
Time frame: Immediately
Substudy 9 - secondary outcome
Time frame: Immediately
Substudy 10 - primary outcome
ARDS will be defined according to the Berlin ARDS criteria: 1) presence of acute hypoxemic respiratory failure defined by a PaO2/FiO2 ratio < 300 mm Hg and PEEP ≥ 5 cm H2O; 2) onset within one week of clinical insult or worsening respiratory symptoms; 3) bilateral consolidations on chest radiography or CT-thorax.
Time frame: Immediately
Substudy 10 - secondary outcome
Clinical examination findings, as well are specified at the study description section.
Biochemical values are serum lactate, creatinine and hemoglobine (see study description).
Hemodynamic variables are obtained from advanced patient monitoring devices, such as invasive central venous or arterial blood pressures, echocardiographic measurements, etc.
Time frame: 90 days
Substudy 11 - primary outcome
Myocardial strain and myocardial strain rates have been measured with the cardiac probe M3S of M4S with default cardiac imaging setting of the General Electric Vivid-S6 mobile ultrasound machine. The measurements were obtained in the AP4CH window with a left ventricle and right ventricle centred view for left and right myocardial strain, respectively.
Time frame: Immediately
Substudy 11 - secondary outcome
Time frame: Immediately
Substudy 11 - secondary outcome
University Medical Center Groningen
Other
Combining Conventional With Advanced Hemodynamic Parameters for Predicting the Outcome of Critically Ill Patients: a Pilot for a Registry
Acronym: SICS-I
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03553069
Acute Disease, Critical Illness
Groningen, Netherlands
View Trial DetailsNCT07020637
Critical Illness, Disease Attributes
Las Vegas, Nevada, United States
View Trial DetailsNCT07411976
Critical Illness, Disease Attributes
Nîmes, France
View Trial DetailsNCT07296029
Confusion, Critical Illness
Kingston, Ontario, Canada
View Trial Details